Pinnacle Associates’s Acumen Pharmaceuticals ABOS Stock Holding History

Pinnacle Associates’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$40K	Buy	18,021 +1	+0%	+$3	﹤0.01%	953
2026 Q2	$48.1K	Hold	18,020	–	–	﹤0.01%	961
2026 Q1	$42.5K	Hold	18,020	–	–	﹤0.01%	950
2025 Q4	$38K	Hold	18,020	–	–	﹤0.01%	926
2025 Q3	$30.8K	Hold	18,020	–	–	﹤0.01%	861
2025 Q2	$20.9K	Hold	18,020	–	–	﹤0.01%	843
2025 Q1	$19.8K	Hold	18,020	–	–	﹤0.01%	820
2024 Q4	$31K	Buy	+18,020	New	+$43.4K	﹤0.01%	830
2024 Q3	–	Sell	-18,020	Closed	-$43.6K	–	801
2024 Q2	$43.6K	Hold	18,020	–	–	﹤0.01%	805
2024 Q1	$73K	Buy	+18,020	New	+$67.9K	﹤0.01%	820
2023 Q4	–	Sell	-18,020	Closed	-$74.8K	–	819
2023 Q3	$74.8K	Hold	18,020	–	–	﹤0.01%	793
2023 Q2	$86.7K	Buy	+18,020	New	+$86.3K	﹤0.01%	793

Other funds holding ABOS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Catalyst Financial Partners Boston, Massachusetts $1.07B AUM 26.85% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13B AUM 35.88% 1-Year Est. Return

PWMAG

Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.71B AUM 23.29% 1-Year Est. Return

Clune & Associates Chicago, Illinois $654M AUM 13.19% 1-Year Est. Return

Pinnacle Associates's ABOS Position: Q3 2026 in Review

Pinnacle Associates increased its Acumen Pharmaceuticals (ABOS) stake by 0.01% in Q3 2026, buying an estimated $3 and bringing the position to 18,021 shares worth $40K. The position accounts for ﹤0.01% of the portfolio, ranked #953.

Pinnacle Associates first reported a position in ABOS in Q2 2023 and has held it in 12 quarters since. The position peaked at $86.7K in Q2 2023. 28 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

Pinnacle Associates held 18,021 shares of Acumen Pharmaceuticals worth $40K as of Q3 2026.
Pinnacle Associates bought 1 Acumen Pharmaceuticals share in Q3 2026, an estimated $3.
Acumen Pharmaceuticals made up ﹤0.01% of Pinnacle Associates's portfolio in Q3 2026, its #953 holding.
Pinnacle Associates first reported a position in Acumen Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Pinnacle Associates's Acumen Pharmaceuticals position peaked at $86.7K in Q2 2023.
28 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on Pinnacle Associates's 13F filing for Q3 2026, filed 20 Oct 2026.